Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025American Journal of HematologyOpen Access

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJuan Carlos Hernández‐BoludaVSVipul ShethSISimona Iacobelli

Discussion

Loading...

Member takes

Overview

Analysis reveals donor type impacts overall survival and graft-versus-host disease in myelofibrosis patients, suggesting treatment optimization.

Key Points

  • Donor type significantly impacts overall survival in myelofibrosis patients after transplantation, leading to varied outcomes depending on donor match.
  • Three-year overall survival rates were 65.8%, 61.5%, 53.2%, and 57.7% for matched sibling, matched unrelated, mismatched unrelated, and haploidentical donors, respectively.
  • The study analyzed 2809 myelofibrosis patients receiving first allogeneic hematopoietic cell transplants, assessing outcomes over a median follow-up of 33.5 months.
  • Increased risks of non-relapse mortality and graft-versus-host disease were noted for mismatched unrelated and haploidentical donors, highlighting treatment differences.

Cite This Study

Hernández‐Boluda et al. (2025) studied this question.

synapsesocial.com/papers/68c1d80554b1d3bfb60faa03https://doi.org/10.1002/ajh.70049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study2024 · 17 citations
  2. 2Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis2025
  3. 3Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT2024 · 2 citations
  4. 4Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes2026 · 1 citations
  5. 5Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation2024 · 3 citations